\BOOKMARK [1][-]{section.1}{Background \046 Introduction}{}% 1
\BOOKMARK [2][-]{subsection.1.1}{The Human Microbiome}{section.1}% 2
\BOOKMARK [2][-]{subsection.1.2}{The Human Metabolism \046 Metabolic Disorder}{section.1}% 3
\BOOKMARK [2][-]{subsection.1.3}{Surrogate Endpoints \046 its Evaluation}{section.1}% 4
\BOOKMARK [2][-]{subsection.1.4}{Aims \046 Objectives}{section.1}% 5
\BOOKMARK [2][-]{subsection.1.5}{Dataset Description, Source and Variables of Interest}{section.1}% 6
\BOOKMARK [2][-]{subsection.1.6}{Notations}{section.1}% 7
\BOOKMARK [1][-]{section.2}{Methods}{}% 8
\BOOKMARK [2][-]{subsection.2.1}{Earlier Methods for Surrogate Endpoint Evaluations and Their Pitfalls}{section.2}% 9
\BOOKMARK [2][-]{subsection.2.2}{Joint Modelling Approach\(JMA\)}{section.2}% 10
\BOOKMARK [2][-]{subsection.2.3}{Causal Inference Approach \(CIA\)}{section.2}% 11
\BOOKMARK [2][-]{subsection.2.4}{Evaluating Use of Multiple Surrogates}{section.2}% 12
\BOOKMARK [2][-]{subsection.2.5}{Softwares and Tools}{section.2}% 13
\BOOKMARK [1][-]{section.3}{Data Analysis}{}% 14
\BOOKMARK [2][-]{subsection.3.1}{Exploratory Analysis}{section.3}% 15
\BOOKMARK [2][-]{subsection.3.2}{Estimation of Treatment Effects}{section.3}% 16
\BOOKMARK [2][-]{subsection.3.3}{Univariate Surrogate Evaluation}{section.3}% 17
\BOOKMARK [3][-]{subsubsection.3.3.1}{Joint Modelling Results}{subsection.3.3}% 18
\BOOKMARK [3][-]{subsubsection.3.3.2}{Causal Inference Results}{subsection.3.3}% 19
\BOOKMARK [2][-]{subsection.3.4}{Multiple Surrogates Evaluation}{section.3}% 20
\BOOKMARK [1][-]{section.4}{Discussion \046 Conclusion}{}% 21
